肾移植耐受诱导的移植物内分子通路研究
本研究分析经生物工程干细胞产品(FCRx)诱导耐受的肾移植受者移植物基因和microRNA表达谱,并与标准免疫抑制(SIS)无排斥、急性排斥及配对供器官比较。FCRx样本未显示T/B细胞介导排斥通路上调,与配对供器官功能基因网络大部分重叠,且抗炎通路激活、促炎调节因子受抑。
要点
- FCRx诱导耐受的移植物无T/B细胞介导排斥通路上调。
- FCRx样本与配对供器官功能基因网络大部分重叠。
- 整合分析可识别调控下游分子通路的上游调节因子。
核心结论
- FCRx诱导耐受的肾移植移植物未显示T/B细胞介导排斥通路上调,且抗炎通路激活、促炎调节因子受抑。
研究设计与样本
- pilot研究,比较FCRx耐受受者、配对供器官移植前样本及SIS无排斥和急性排斥受者的肾活检基因与microRNA表达谱。
主要发现
- FCRx样本无T/B细胞介导排斥通路上调,与配对供器官功能基因网络大部分重叠。
- 与SIS样本相比,FCRx样本B细胞受体信号等通路基因上调,促炎调节因子预测受抑、抗炎通路激活。
- 整合microRNA与基因表达分析识别出下调炎症通路、维持组织稳态的调节因子。
临床怎么用
- 移植物内分子评估可用于监测FCRx诱导耐受相关通路。
- 整合分析有助于识别调控下游分子通路的上游调节因子。
局限性
- 为初步研究,样本量未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The modern immunosuppression regimen has greatly improved short-term allograft outcomes but not long-term allograft survival. Complications associated with immunosuppression, specifically nephrotoxicity and infection risk, significantly affect graft and patient survival. Inducing and understanding pathways underlying clinical tolerance after transplantation are, therefore, necessary. We previously showed full donor chimerism and immunosuppression withdrawal in highly mismatched allograft recipients using a bioengineered stem cell product (FCRx). Here, we evaluated the gene expression and microRNA expression profiles in renal biopsy samples from tolerance-induced FCRx recipients, paired donor organs before implant, and subjects under standard immunosuppression (SIS) without rejection and with acute rejection. Unlike allograft samples showing acute rejection, samples from FCRx recipients did not show upregulation of T cell- and B cell-mediated rejection pathways. Gene expression pathways differed slightly between FCRx samples and the paired preimplantation donor organ samples, but most of the functional gene networks overlapped. Notably, compared with SIS samples, FCRx samples showed upregulation of genes involved in pathways, like B cell receptor signaling. Additionally, prediction analysis showed inhibition of proinflammatory regulators and activation of anti-inflammatory pathways in FCRx samples. Furthermore, integrative analyses (microRNA and gene expression profiling from the same biopsy sample) identified the induction of regulators with demonstrated roles in the downregulation of inflammatory pathways and maintenance of tissue homeostasis in tolerance-induced FCRx samples compared with SIS samples. This pilot study highlights the utility of molecular intragraft evaluation of pathways related to FCRx-induced tolerance and the use of integrative analyses for identifying upstream regulators of the affected downstream molecular pathways.
引用
- Gallon L, Mathew JM, Bontha SV, et al. Intragraft Molecular Pathways Associated with Tolerance Induction in Renal Transplantation. J Am Soc Nephrol. 2017. PMID: 29191961. doi:10.1681/ASN.2017030348
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。